JO
KNSA icon

John Overdeck’s Kiniksa Pharmaceuticals KNSA Stock Holding History

John Overdeck’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.9M Buy
561,480
+140,566
+33% +$7.29M 0.03% 714
2026
Q1 		$20.3M Sell
420,914
-109,582
-21% -$4.85M 0.02% 938
2025
Q4 		$21.9M Buy
530,496
+68,726
+15% +$2.76M 0.03% 692
2025
Q3 		$17.9M Buy
461,770
+298,030
+182% +$9.68M 0.03% 673
2025
Q2 		$4.53M Buy
+163,740
New +$4.17M 0.01% 1278
2021
Q3 		– Sell
-49,232
Closed -$686K – 4485
2021
Q2 		$686K Buy
+49,232
New +$748K ﹤0.01% 2823
2021
Q1 		– Sell
-55,826
Closed -$986K – 4045
2020
Q4 		$986K Sell
55,826
-219,618
-80% -$3.86M ﹤0.01% 2023
2020
Q3 		$4.22M Buy
275,444
+204,219
+287% +$3.83M 0.02% 881
2020
Q2 		$1.81M Buy
71,225
+52,436
+279% +$1.1M 0.01% 1150
2020
Q1 		$291K Buy
18,789
+578
+3% +$9.04K ﹤0.01% 2327
2019
Q4 		$201K Buy
+18,211
New +$158K ﹤0.01% 3420
2018
Q4 		– Sell
-13,442
Closed -$343K – 3275
2018
Q3 		$343K Buy
+13,442
New +$261K ﹤0.01% 2687

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

John Overdeck's KNSA Position: Q2 2026 in Review

John Overdeck increased its Kiniksa Pharmaceuticals (KNSA) stake by 33% in Q2 2026, buying an estimated $7.29M and bringing the position to 561,480 shares worth $35.9M. The position accounts for 0.03% of the portfolio, ranked #714.

John Overdeck first reported a position in KNSA in Q3 2018 and has held it in 12 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • John Overdeck held 561,480 shares of Kiniksa Pharmaceuticals worth $35.9M as of Q2 2026.
  • John Overdeck bought 140,566 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $7.29M.
  • Kiniksa Pharmaceuticals made up 0.03% of John Overdeck's portfolio in Q2 2026, its #714 holding.
  • John Overdeck first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.